ADC Therapeutics (ADCT) Cash from Operations (2020 - 2026)
ADC Therapeutics (ADCT) posted Cash from Operations of 29710000.0 for Q1 2026, up 4.54% sequentially from 31123000.0 in Q4 2025, and up 47.26% YoY from 20175066.18 in Q1 2025.
ADC Therapeutics (ADCT) Cash from Operations (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 29710000.0 in Q1 2026.
- Quarterly Cash from Operations rose 47.26% year-over-year to 29710000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 114550000.0 (up 15.82% YoY) and the FY2025 annual result came in at 141174000.0, down 14.0% from the prior year.
- Cash from Operations improved to 29710000.0 in Q1 2026 per ADCT's latest filing, from 31123000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2195000.0 in Q3 2022 and troughed at 56334000.0 in Q1 2025.
- A 5-year average of 32453882.35 and a median of 31633000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 103.75% in 2022, then slumped 1770.75% in 2023.
- Over 5 years, Cash from Operations stood at 53614000.0 in 2022, then surged by 41.0% to 31633000.0 in 2023, then soared by 30.92% to 21852000.0 in 2024, then sank by 42.43% to 31123000.0 in 2025, then gained by 4.54% to 29710000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 29710000.0, 31123000.0, and 29630000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | -11.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.81 Mn |
| Jun 30, 2026 | -11.81 Mn |
| Mar 31, 2026 | -29.71 Mn |
| Mar 31, 2026 | -29.71 Mn |
| Dec 31, 2025 | -31.12 Mn |
| Dec 31, 2025 | -31.12 Mn |
| Sep 30, 2025 | -29.63 Mn |
| Sep 30, 2025 | -29.63 Mn |
| Jun 30, 2025 | -24.09 Mn |
| Jun 30, 2025 | -24.09 Mn |
| Mar 31, 2025 | -56.33 Mn |
| Mar 31, 2025 | -56.33 Mn |
| Dec 31, 2024 | -21.85 Mn |
| Dec 31, 2024 | -21.85 Mn |
| Sep 30, 2024 | -25.04 Mn |
| Sep 30, 2024 | -25.04 Mn |
| Jun 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -32.85 Mn |
| Mar 31, 2024 | -44.10 Mn |
| Mar 31, 2024 | -44.10 Mn |